

NEURONETICS

FOR IMMEDIATE RELEASE

Neuromodulation Trailblazer Neuronetics, Inc. Names Two Life Sciences Leaders to its Board of Directors

Healthcare veteran Glenn Muir and industry executive Paulina Hill to join the Neuronetics Board

Malvern, Pa., August 21, 2017 – [Neuronetics, Inc.](http://www.neuronetics.com), a privately held medical device company widely recognized as the market-leader in transcranial magnetic stimulation (TMS) therapy, with its NeuroStar® Advanced Therapy for depression, announced today it has appointed Glenn Muir, former Executive Vice President and Chief Financial Officer of life sciences pioneer Hologic, Inc., to its Board of Directors. In his new role, Muir will serve as the Audit Committee Chair in addition to his participation as an independent director.

“In addition to specific experience with companies at our stage, Glenn brings essential financial and industry expertise, important relationships and public market perspective to our Board as we seek to continue our growth trajectory,” said Brian Farley, Chairperson of the Neuronetics Board of Directors. “We are excited to welcome him to the Neuronetics team.”

Muir brings nearly 30 years of experience in finance and accounting management in the medical technology industry, most recently serving as Executive Vice President and Chief Financial Officer of Hologic. Through his financial expertise and guidance, Muir helped the advanced technologies provider achieve revenues over \$2.5 billion and an enterprise value exceeding \$10 billion. Having spent time in the healthcare space working in medical imaging, diagnostics and surgical solutions, Muir has steered two companies through initial public offerings, raised over \$5 billion in debt and led the acquisition and integration of over 20 companies.

“Neuronetics is a perfect fit for me, and I am honored to join this innovative healthcare success story,” said Muir. “I look forward to applying my experience to help broaden the use of the company’s transformative NeuroStar Advanced Therapy TMS technology, as it offers patients a chance for long-term remission from depression.¹”

A licensed CPA, Muir earned a Master of Business Administration from Harvard University and a master’s degree in taxation from Bentley College. In addition to his Board of Directors role at Neuronetics, Muir serves as a member of the Board of Directors and the Audit Committee Chair at Repligen Corporation, ReWalk Robotics Ltd. and G1 Therapeutics, Inc.

¹ Dunner DL, et al. J Clin Psych, (2014)

NEURONETICS

Also joining the Neuronetics Board of Directors is Paulina Hill, Principal of Polaris Partners and founding Chief Executive Officer of Polaris-backed Marauder Therapeutics. Hill currently serves on the Board of Directors at Arsenal Medical, Faraday Pharmaceuticals, Kala Pharmaceuticals, KinDex Pharmaceuticals and Marauder Therapeutics. Prior to joining Polaris, Hill completed her postdoctoral fellowship in chemical engineering at the Massachusetts Institute of Technology. She earned a PhD in molecular medicine at Wake Forest University School of Medicine and a bachelor's degree from East Carolina University majoring in biochemistry, neuroscience, biology and chemistry.

To learn more about Neuronetics and how its NeuroStar Advanced Therapy has been used to treat more than 50,000 patients, visit www.NeuroStar.com.

About Neuronetics, Inc.

Neuronetics, Inc. is a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. Based in Malvern, PA, Neuronetics, Inc. is the leader in transcranial magnetic stimulation (TMS) with its development of NeuroStar® Advanced Therapy, a noninvasive form of neuromodulation. For more information, please visit www.neurostar.com.

NeuroStar® is a registered trademark of Neuronetics, Inc.

About NeuroStar® Advanced Therapy

NeuroStar® Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. NeuroStar Advanced Therapy is the #1 physician-preferred TMS treatment for patients with MDD, and there are over 800 NeuroStar systems in 49 states.

With over 300 million covered lives, NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.

NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment ($P = 0.0173$; odds ratio = 4.05).² The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in

² George MS, et al. Arch Gen Psychiatry, (2010)

NEURONETICS

people with non-removable conductive metal in or near the head. Long term durability of effect has not been established in a randomized controlled trial.

For more information and full safety and prescribing information, visit www.neurostar.com.

Media Contacts:

Meagan Dominick

Office: 610-455-2779

Mobile: 773-369-4255

mdominick@vaultcommunications.com